

TOWER Study Details

Agent: teriflunomide

Treatment mode of action: Immune modulator (reduces immune system over activity)

Study Description/Purpose: A randomized, double-blind, placebo-controlled, parallel group study to evaluate the effectiveness and safety of two doses of teriflunomide versus placebo in people with relapsing forms of MS.

Institution(s): Multiple, worldwide

Type of MS: Relapsing

Number of Subjects: 1110

Funding: sanofi-aventis

Website: Go to www.tower3.msstudies.com for additional details about the study

TOWER Locations & Contact Information

Australia: <http://www.mstrial.org.au/find-a-ms-trial/>

Belarus: Iryna Alokchina, ia@verumua.com

France: Helene.merle@chu-lyon.fr

Mexico:

- Dr. Jose Manuel Aleman Pedroza; jaleman@uag.mx; Hospital Dr. Angel Leño
- Dr. Ildefonso Rodríguez Leyva; neurologiahc@prodigy.net.mx; Hospital Ignacio Morones Prieto
- Dr. Arturo Violante Villanueva; aviolantev@yahoo.com.mx; Instituto Nacional de Neurología y Neurocirugía, Clínica de Esclerosis Múltiple
- Dr. Minerva López Ruíz; lopez69ruiz@hotmail.com; Hospital General de México
- Dr. Juan Fernando Gongora Rivera; fernando.gongora@hotmail.com; Hospital Universitario "Dr. Jose Eleuterio Gonzalez"

Morocco: Pr Ouhabi; ouhabiha@hotmail.com

Thailand: JT.Tibung@sanofi-aventis.com

Tunisia: Riadh Gouider; rg@gnet.tn

Turkey: Prof. Dr. Gülşen F.Akman Demir; akmandem@istanbul.edu.tr

Ukraine: Iryna Alokchina, ia@verumua.com

United States: www.tower3.msstudies.com

***This study is also being conducted in:** Austria, Belgium, Canada, Chile, China, Czech Republic, Estonia, Germany, Greece, Netherlands, Philippines, Poland, Romania, Slovakia, South Africa, Spain, Sweden, and the United Kingdom